Phelan-McDermid syndrome (PMS) is a genetic neurodevelopmental disorder caused by a microdeletion within chromosome 22q13.3 1–6, and accounts for ∼1-3% of cases of autism spectrum disorders (ASD). Individuals with PMS typically present with neonatal hypotonia, severe speech delay, intellectual disability, motor impairments, and autism-related features, although additional manifestations such as epilepsy, sleep disturbances, and developmental regression are common. As in ASD, there is considerable heterogeneity in cognitive and behavioral impairments in PMS, making it difficult to determine which features arise directly from SHANK3/Shank3 deficiency and how deficits manifest across development. In the present study, we transferred the targeted Shank3 mutation, previously characterized on the Sprague Dawley background, onto the Long-Evans strain and performed a longitudinal behavioral assessment of Shank3-deficient rats from infancy to adulthood. The rats were evaluated for delays in early sensory and motor development, and ultrasonic vocalizations as neonates, social behavior, short term memory and gait as juveniles, and cognitive-executive dysfunction using a touchscreen-based visual discrimination and reversal learning task as adults. Despite profound reductions and/or complete loss of Shank3 protein expression, heterozygous and homozygous male and female rats showed normal physical and neurological reflexes across development, yet female Shank3 knockout pups showed a selective reduction in distress-associated ultrasonic vocalizations. As juveniles, subtle abnormalities emerged in short-term memory and limb coordination, while social preference for novelty and recognition was normal. Prominent behavioral abnormalities were observed in adults characterized by rapid and error-prone responding to visual stimuli during discrimination learning and reversal. These data suggest that rats with complete or partial Shank3 deficiency produce a selective behavioral profile in which high-order cognitive dysfunction is more pronounced than deficits in basic sensorimotor or select social behaviors. More broadly, these findings highlight executive dysfunction as a key consequence of the loss of Shank3. For the first time, we report the loss of Shank3 expression on a Long-Evans background strain as a valuable translational tool for investigating cognitive dysfunction and therapeutic windows in Shank3-associated disorders.
Anna C. Pearson, T. Drazan, Sean P. Bradley et al.· bioRxiv· 0 citations
De novo mutations in protein-coding regions are strongly associated with autism, and family-based sequencing studies have identified numerous genes that harbor excess mutations in probands. However, the aggregate contribution of this class of variation to autism remains unclear. Here, we model the distribution of de novo autosomal coding variant effect sizes in 38,680 autism trios to estimate fundamental features of de novo genetic architecture. We find that damaging de novo single-nucleotide variants and frameshift indels explain 3.4% (95% CI: 2.1% - 4.7%) of autism variance on the observed scale. Approximately 7.0% (95% CI: 5.6% - 8.4%) of cases carry a large-effect mutation (rate ratio > 5), and most such mutations are incompletely penetrant. Although hundreds of genes make some nonzero contribution, 50% of mutational variance on the autosomes is explained by just 15 genes. De novo enrichments vary across cohorts with different ascertainment strategies; making projections for future trio studies, we show that many large-effect genes remain to be found.
A. Nadig, J. Fu, F. Satterstrom et al.· medRxiv· 0 citations
This study showcases the complexities and novel findings derived from a decade-long analysis of 419 Italian NDD patient-parent trios, and underscores that navigating the complexities of large NDD cohorts requires a detailed, expert-driven approach to enhance diagnostic yield.
Simona Cardaropoli, Lisa Pavinato, Slavica Trajkova et al.· Human Genetics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.